Previous 10 | Next 10 |
2023-09-13 10:00:09 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
2023-09-13 08:18:57 ET Losers: Nature Wood Group Limited ( NWGL ) -15% on prices $6.75M equity offering . Evolution Petroleum Corporation ( EPM ) -13% . after Q4 earning release . Applied Optoelectronics ( AAOI ) -13% amends equity pact with R...
2023-09-11 12:44:57 ET More on Plus Therapeutics Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeutics Plus Therapeutics Q2 2023 Earnings Call Transcript Bio...
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today anno...
2023-09-08 08:38:43 ET More on Biocept, Plus, etc. Biocept, Inc. ( BIOC ) Business Update Conference Call (Transcript) Plus Therapeutics, Inc. ( PSTV ) Q2 2023 Earnings Call Transcript For further details see: Biocept gains on licensing pact with Plus The...
CNSide™ assay is the gold standard diagnostic cerebrospinal fluid (CSF) assay for patients with suspected central nervous system (CNS) cancers As part of the agreement, Plus obtains a nonexclusive license and option for exclusivity for patients receiving CNS radiotherapy ...
AUSTIN, Texas, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today anno...
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., Preside...
2023-08-14 21:52:02 ET Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Conference Call August 14, 2023 17:00 ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants ...
2023-08-14 16:07:41 ET More on Plus Therapeutics Plus stock rises as radiotherapy shows promise in ongoing brain cancer studies Plus Therapeutics Q3 net loss widens Y/Y Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating Plus Therapeutics fina...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...